| アブストラクト | AIMS: The aim of this study was to monitor the trajectories of antidepressant use during pregnancy and the postpartum period among women chronically treated with antidepressants before their pregnancy, and to assess characteristics associated with each trajectory. METHODS: This cohort study included all pregnant women whose data were included in the General Sample of Beneficiaries (EGB) database affiliated with the French Health Insurance System, from 2009 to 2014. Women were followed up until 6 months after childbirth. Chronic treatment was defined as exposure over the 6-month period preceding pregnancy. A group-based trajectory model (GBMT) was estimated to identify distinctive longitudinal profiles of antidepressant use. RESULTS: Among 760 women chronically treated with antidepressants before their pregnancy, 55.8% stopped their treatment permanently in the first trimester, 20.4% discontinued it for a minimum of 3 months and resumed it postpartum, and 23.8% maintained it throughout pregnancy and postpartum. No sociodemographic or medical characteristics were associated with any trajectory group. Women who maintained treatment presented more frequent obstetric complications and postpartum psychiatric disorders. Among women who interrupted treatment, prescription of benzodiazepines and anxiolytics decreased initially but rose postpartum to a higher level than before pregnancy. CONCLUSIONS: Pregnant women treated with antidepressant require a re-evaluation of psychiatric treatment. It is necessary to pay attention to obstetric complications for severely depressed women. Additionally, as relapse was associated with increased benzodiazepine use, it is important to carefully monitor all women who stop antidepressant treatment during pregnancy. |
|---|
| 投稿者 | Cabaillot, Aurelie; Bourset, Alexandra; Mulliez, Aurelien; Delorme, Jessica; Orri, Massimiliano; Vicard-Olagne, Mathilde; Zenut, Marie Christine; Tournier, Marie; Gallot, Denis; Authier, Nicolas; Chenaf, Chouki; Laporte, Catherine |
|---|
| 組織名 | Departement de Medecine Generale, UFR de Medicine, Universite Clermont Auvergne,;Clermont-Ferrand, France.;CHU Clermont-Ferrand, Inserm, Neuro-Dol, Service de Pharmacologie medicale,;Centres Addictovigilance et Pharmacovigilance, Observatoire Francais des;Medicaments Antalgiques (OFMA), Institut Analgesia, Universite Clermont Auvergne,;Delegation a la recherche clinique et a l'innovation, CHU Clermont-Ferrand,;McGill Group for Suicide Studies, Douglas Mental Health University Institute,;Department of Psychiatry, McGill University, Montreal, QC, Canada.;Bordeaux Population Health Research Centre, Inserm U1219, Universite de Bordeaux,;Bordeaux, France.;Npsysydo, Universite Clermont Auvergne, Clermont-Ferrand, France.;Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology,;Universite de Bordeaux, Bordeaux, France.;Hospital Charles Perrens, Bordeaux, France.;CNRS 6293, INSERM 1103, GReD, QC G1V 0A6 Clermont-Ferrand; Department of;Obstetrics and Gynecology, CHU Clermont-Ferrand, Faculty of Medicine, Universite;Clermont-Auvergne, Clermont-Ferrand, France. |
|---|
